Medications

Adding subcutaneous daratumumab slows advanced multiple myeloma

(HealthDay)—For patients with relapsed/refractory multiple myeloma (RRMM), subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) reduces the risk of progression or death compared with Pd alone, according to ...

Oncology & Cancer

Stem cell transplant benefits older adults with MDS

(HealthDay)—Among older patients with myelodysplastic syndrome (MDS), survival rates are better for those undergoing allogeneic hematopoietic cell transplantation (HCT), according to a study presented at the annual meeting ...

Medications

Triplet therapy slows refractory multiple myeloma

(HealthDay)—A once-weekly regimen of selinexor, bortezomib, and dexamethasone slows the progression of relapsed or refractory multiple myeloma, according to a study published in the Nov. 14 issue of The Lancet.

Oncology & Cancer

Laparoscopic resection may be an option for CRC liver metastases

(HealthDay)—For patients with metastatic colorectal cancer who have resectable liver metastases, survival outcomes at five years do not differ significantly for treatment with laparoscopic versus open liver resection, according ...

Oncology & Cancer

Trial targets deadly lung cancer

With more than 650 Australians diagnosed with malignant mesothelioma last year, Flinders University is leading new research to discover alternatives to chemotherapy and even prevent deaths by early detection in future.

page 26 from 40